Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading ENVB daily closes…
Loading price history…
Pipeline assets
EB-003
Preclinical · Active
Target 5-HT2A / 5-HT1B receptors
Partnerships License from Diverse Biotech (paid-up; no further liability on commercialization)
Indications
Difficult-to-address mental health disorders (depression, anxiety)(Preclinical)
Status note Lead drug candidate of the EVM301 Series; novel derivative of DMT (N,N-Dimethyltryptamine) designed to promote neuroplasticity without hallucinogenic effects. IND-enabling activities advanced in Q2 2026 toward planned first-in-human clinical studies; EVM401 Series remains a secondary focus.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
Ikarian Capital
100,002
+100,002
0.02%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.